循环DNA在大肠癌中的应用

摘要/Abstract

摘要： 循环DNA是一种存在于血浆、脑脊液及滑液等体液中的细胞外DNA。肿瘤患者循环DNA的含量明显高于健康人群，并具有与肿瘤发生、发展相关的特征性改变，例如基因突变、DNA甲基化、微卫星不稳定性等。循环DNA的定量与定性检测，在肿瘤的筛查、诊断、病情的监测以及预后评价中均有潜在的价值。

关键词: 结直肠肿瘤, 循环DNA

Abstract: Circulating DNA is defined as a kind of extracellular DNA that exists in plasma，cerebrospinal fluid and synovial fluid. The concentration of circulating DNA of cancer patients is significantly higher than that in healthy people. The genetic and epigenetic alterations of circulating cellfree nucleic acids are relevant to cancer development and progression, for example, gene mutation, DNA methylation and microsatellite instability and so on. The quantitative and qualitative detection of circulating DNA shows promising potential value in cancer screening, diagnosis, disease monitoring treatment and prognosis.

Key words: Colorectal neoplasms, Circulating DNA

黄宗华, 徐丹丹, 张飞艳, 宋丽华, 宋现让. 循环DNA在大肠癌中的应用[J]. 国际肿瘤学杂志, 2016, 43(2): 152-.

HUANG Zong-Hua, XU Dan-Dan, ZHANG Fei-Yan, SONG Li-Hua, SONG Xian-Rang. Application of circulating DNA in colorectal cancer[J]. Journal of International Oncology, 2016, 43(2): 152-.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI:10.3322/caac.20107. ［2］ Schwarzenbach H, Hoon DS, Pantel K. Cellfree nucleic acids as biomarkers in cancer patients［J］. Nat Rev Cancer, 2011, 11(6): 426437. DOI:10.1038/nrc3066. ［3］ Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients［J］. Expert Opin Biol Ther, 2012, 12Suppl 1: S209S215. DOI:10.1517/14712598.2012.688023. ［4］ Bernatsky S, RamseyGoldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment［J］. Ann Rheum Dis, 2014, 73(1): 138142. DOI:10.1136/annrheumdis2012202099. ［5］ Kaiser J. Medicine. Keeping tabs on tumor DNA［J］.Science, 2010, 32(5969): 1074. DOI: 10.1126/science.327.5969.1074. ［6］ Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection［J］. Am J Gastroenterol, 2008, 103(11): 28622870. DOI:10.1111/j.15720241.2008.02088.x. ［7］ Kanthan R, Senger JL, Kanthan SC. Fecal molecular markers for colorectal cancer screening［J］. Gastroenterol Res Pract, 2012 (2011): 184343. DOI:10.1155/2012/184343. ［8］ Hao TB, Shi W, Shen XJ, et al. Circulating cellfree DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer［J］. Br J Cancer, 2014, 111(8): 14821489. DOI:10.1038/bjc.2014.470. ［9］ Danese E, Montagnana M, Minicozzi AM, et al. Realtime polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers［J］. Clin Chem Lab Med, 2010, 48(11): 16651668. DOI:10.1515/CCLM.2010.301. ［10］ Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer［J］. Clin Cancer Res, 2006, 12(23): 69856988. DOI:10.1158/10780432.CCR061931. ［11］ Holdenrieder S, Dharuman Y, Standop J, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer［J］. Anticancer Res, 2014, 34(5): 23572362. ［12］闫巍, 徐智. 结直肠癌TNM分期与循环DNA水平关系的临床研究［J］. 中国微创外科杂志, 2012, 12(6): 512514. ［13］ Mouliere F, El Messaoudi S, Pang D, et al. Multimarker analysis of circulating cellfree DNA toward personalized medicine for colorectal cancer［J］. Mol Oncol, 2014, 8(5): 927941. DOI:10.1016/j.molonc.2014.02.005. ［14］ Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA［J］. Nat Med, 2014, 20(4): 430435. DOI:10.1038/nm.3511. ［15］ Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cellfree DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan［J］. Clin Cancer Res, 2012, 18(4): 11771185. DOI:10.1158/10780432.CCR110564. ［16］ Kuo YB, Chen JS, Fan CW, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cellfree DNA in plasmas of patients with colorectal cancer［J］. Clin Chim Acta, 2014, 433(433): 284289. DOI:10.1016/j.cca.2014.03.024. ［17］闫巍, 张能维, 徐智, 等. 结直肠癌患者手术前后循环DNA水平的变化及其意义［J］. 中国普通外科杂志, 2013, 22(12): 16271630. DOI:10.7659/j.issn.10056947.2013.12.021. ［18］ Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cellfree DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy［J］. Ann Surg Oncol, 2011, 18(9): 24612468. DOI:10.1245/s104340111638y. ［19］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI:10.1126/scitranslmed.3007094. ［20］ Lefebure B, Charbonnier F, Di Fiore F, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer［J］. Ann Surg, 2010, 251(2): 275280. DOI:10.1097/SLA.0b013e3181c35c87.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[6]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[7]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[8]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[9]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[10]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[11]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.
[12]	高一钊, 刘洋, 刘秋龙, 邢金良. 循环游离核酸在结直肠癌临床诊疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 555-559.
[13]	何哲锋, 吴燚阳, 李振军, 应晓江. 炎性相关标志物对结直肠癌的预测价值[J]. 国际肿瘤学杂志, 2022, 49(9): 560-563.
[14]	赵莹, 张革红. AGR、PLR及NLR变化与转移性结直肠癌化疗疗效的相关性研究[J]. 国际肿瘤学杂志, 2022, 49(8): 473-477.
[15]	黄梦盼, 王学红, 芦永福. FOXA2在结直肠癌中的作用机制及其在诊疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(8): 490-493.